Effects of low-dose continuous combined HRT on vascular function in women with type 2 diabetes

Diabetes & Vascular Disease Research

Volumn 1, Issue 2, 2004, Pages 82-88

  Kernohan, Andrew Fb ^a   Spiers, Angela ^a   Sattar, Naveed ^a   Hillier, Chris ^b   Cleland, Steve J ^a   Small, Michael ^c   Lumsden, Mary Ann ^a   Connell, John Mc ^a   Petrie, John R ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b GLASGOW CALEDONIAN UNIVERSITY   (United Kingdom)

^c GARTNAVEL GENERAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ESTRADIOL; INTERCELLULAR ADHESION MOLECULE 1; NORETHISTERONE; VASCULAR CELL ADHESION MOLECULE 1;

ARTERY; ARTICLE; BIOPSY; BLOOD FLOW VELOCITY; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG COMBINATION; DRUG EFFECT; ESTROGEN THERAPY; FEMALE; HUMAN; METABOLISM; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOLOGY; PATHOPHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; VASCULAR ENDOTHELIUM; VASCULAR RESISTANCE; VASOCONSTRICTION; VASODILATATION;

ARTERIES; BIOPSY; BLOOD FLOW VELOCITY; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; ENDOTHELIUM, VASCULAR; ESTRADIOL; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; INTERCELLULAR ADHESION MOLECULE-1; MIDDLE AGED; NORETHINDRONE; VASCULAR CELL ADHESION MOLECULE-1; VASCULAR RESISTANCE; VASOCONSTRICTION; VASODILATION;

EID: 33644674341     PISSN: 14791641     EISSN: None     Source Type: Journal    
DOI: 10.3132/dvdr.2004.012     Document Type: Article

References (64)

1. Vallance P. Nitric oxide in the human cardiovascular system. Br J Clin Pharmacol 1998; 45: 433–439.
2. McVeigh GE, Brennan GM, Johnston GD et al. Impaired endothelium-dependent and independent vasodilation in patients with type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 1992; 35: 771–776.
3. Williams SB, Cusco JA, Roddy MA, Johnstone MT, Creager MA. Impaired nitric oxide-mediated vasodilation in patients with non-insulin-dependent diabetes mellitus. J Am Coll Cardiol 1996; 27: 567–574.
4. Enderle MD, Benda N, Schmuelling RM, Haering HU, Pfohl M. Preserved endothelial function in IDDM patients, but not in NIDDM patients, compared with healthy subjects [comment]. Diabetes Care 1998; 21: 271–277.
5. Gazis A, White DJ, Page SR, Cockcroft JR. Effect of oral vitamin E (alpha-tocopherol) supplementation on vascular endothelial function in Type 2 diabetes mellitus. Diabetic Med 1999; 16: 304–311.
6. Vehkavaara S, Makimattila S, Schlenzka A, Vakkilainen J, Westerbacka J, Yki-Jarvinen H. Insulin therapy improves endothelial function in type 2 diabetes. Arterioscler Thromb Vasc Biol 2000; 20: 545–550.
7. Barrett-Connor EL, Cohn BA, Wingard DL, Edelstein SL. Why is diabetes mellitus a stronger risk factor for fatal ischemic heart disease in women than in men? The Rancho Bernardo Study. JAMA 1991; 265: 627–631.
8. Mercuro G, Longu G, Zoncu S, Cherchi A. Impaired forearm blood flow and vasodilator reserve in healthy postmenopausal women. Am Heart J 1999; 137: 692–697.
9. Caulin-Glaser T, Garcia-Cardena G, Sarrel P, Sessa WC, Bender JR. 17–estradiol regulation of human endothelial cell basal nitric oxide release, independent of cytosolic Ca2+ mobilization. Circ Res 1997; 81: 885–892.
10. Chen Z, Yuhanna IS, Galcheva-Gargova Z, Karas RH, Mendelsohn ME, Shaul PW. Estrogen receptor (alpha) mediates the nongenomic activation of endothelial nitric oxide synthase by estrogen. J Clin Invest 1999; 103: 401–406.
11. Darkow DJ, Lu L, White RE. Estrogen relaxation of coronary artery smooth muscle is mediated by nitric oxide and cGMP. Am J Physiol 1997; 272: H2765–H2773.
12. Kim HP, Lee JY, Jeong JK, Bae SW, Lee HK, Jo I. Nongenomic stimulation of nitric oxide release by estrogen is mediated by estrogen receptor alpha localized in caveolae. Biochem Biophys Res Commun 1999; 263: 257–262.
13. Mendelsohn ME. Nongenomic, ER-mediated activation of endothelial nitric oxide synthase: how does it work? What does it mean?. Circ Res 2000; 87: 956–960.
14. Bucci M, Roviezzo F, Cicala C, Pinto A, Cirino G. 17-beta-oestradiol-induced vasorelaxation in vitro is mediated by eNOS through hsp90 and akt/pkb dependent mechanism. Br J Pharmacol 2002; 135: 1695–1700.
15. Mercuro G, Vitale C, Fini M, Zoncu S, Leonardo F, Rosano G.M. Lipid profiles and endothelial function with low-dose hormone replacement therapy in postmenopausal women at risk for coronary artery disease: a randomized trial. Internat J Cardiol 2003; 89: 257–265.
16. Ossewaarde ME, Bots ML, van der Schouw YT et al. Does the beneficial effect of HRT on endothelial function depend on lipid changes?. Maturitas 2003; 45(1):7–54.
17. Gambacciani M, Monteleone P, Vitale C et al. Dydrogesterone does not reverse the effects of estradiol on endothelium-dependant vasodilation in postmenopausal women: a randomised clinical trial. Maturitas 2002; 43: 117–123.
18. Sanada M, Higashi Y, Nakagawa K et al. A comparison of low-dose and standard-dose oral estrogen on forearm endothelial function in early postmenopausal women. J Clin Endocrinol Metab 2003; 88: 1303–1309.
19. Guzic-Salobir B, Keber I, Seljeflot I, Arnesen H, Vrabic L. Combined hormone replacement therapy improves endothelial function in healthy postmenopausal women. J Intern Med 2001; 250: 508–515.
20. Lim SC, Caballero AE, Arora S et al. The effect of hormonal replacement therapy on the vascular reactivity and endothelial function of healthy individuals and individuals with type 2 diabetes. J Clin Endocrinol Metab 1999; 84: 4159–4164.
21. Perera M, Sattar N, Petrie JR et al. The effects of transdermal estradiol in combination with oral norethisterone on lipoproteins, coagulation, and endothelial markers in postmenopausal women with type 2 diabetes: a randomized, placebo-controlled study. J Clin Endocrinol Metab 2001; 86: 1140–1143.
22. Koh KK, Kang MH, Jin DK et al. Vascular effects of estrogen in type II diabetic postmenopausal women. J Am Coll Cardiol 2001; 38: 1409–1415.
23. Hulley S, Grady D, Bush T et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 1998; 280: 605–613.
24. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002; 288: 321–333.
25. Furberg CD, Vittinghoff E, Davidson M et al. Subgroup interactions in the Heart and Estrogen/Progestin Replacement Study: lessons learned.[comment]. Circulation 2002; 105: 917–922.
26. Manson JE, Hsia J, Johnson KC et al. Estrogen plus Progestin and the risk of coronary heart disease. N Engl J Med 2003; 349: 523–534.
27. Herrington DM, Howard TD. From presumed benefit to potential harm–hormone therapy and heart disease.[comment]. New Engl J Med 2003; 349: 519–521.
28. Ferrara A, Quesenberry CP, Karter AJ, Njoroge CW, Jacobson AS, Selby JV. Current use of unopposed estrogen and estrogen plus progestin and the risk of acute myocardial infarction among women with diabetes: the Northern California Kaiser Permanente Diabetes Registry, 1995–1998. Circulation 2003; 107: 43–48.
29. Kelly JG, Spiers A, Gould GW, Petrie JR, Lyall H, Connell JMC. Altered vascular function in young women with polycystic ovary syndrome. J Clin Endocrinol Metab 2002; 87: 742–746.
30. Cruickshank K, Riste L, Anderson SG, Wright JS, Dunn G, Gosling R.G. Aortic pulse-wave velocity and its relationship to mortality in diabetes and glucose intolerance: an integrated index of vascular function?. Circulation 2002; 106: 2085–2090.
31. Padmanabhan N, Jardine AG, McGrath JC, Connell JM. Angiotensin-converting enzyme-independent contraction to angiotensin I in human resistance arteries. Circulation 1999; 99: 2914–2920.
32. Staessen JA, van der Heijden-Spek JJ et al. Menopause and the characteristics of the large arteries in a population study. J Hum Hypertens 2001; 15: 511–518.
33. Samaras K, Hayward CS, Sullivan D, Kelly RP, Campbell LV. Effects of postmenopausal hormone replacement therapy on central abdominal fat, glycemic control, lipid metabolism, and vascular factors in type 2 diabetes: a prospective study. Diabetes Care 1999; 22: 1401–1407.
34. Mares P, Dauzat M, Abramovici Y. Hormone replacement therapy with estradiol valerate and cyproterone acetate: effects on endothelium-dependent vasodilatation and arterial wall compliance. Maturitas 2002; 42(1):45–53.
35. Teede HJ, Liang YL, Kotsopoulos D, Zoungas S, Cravent R, McGrath BP. A placebo-controlled trial of long-term oral combined continuous hormone replacement therapy in postmenopausal women: effects on arterial compliance and endothelial function. Clin Endocrinol 2001; 55: 673–682.
36. Hillier C, Petrie MC, Love MP, Johnston F, MacLean MR, McMurray JJ. Effect of adrenomedullin on the production of endothelin-1 and on its vasoconstrictor action in resistance arteries: evidence for a receptor-specific functional interaction in patients with heart failure. Clin Sci 2001; 101(1):45–51.
37. Perera M, Petrie JR, Hillier C, Small M, Connell JMC, Lumsden MA. Hormone replacement therapy can augment vascular relaxation in post-menopausal women with type 2 diabetes. Human Reproduction 2002; 17: 497–502.
38. Rodstrom K, Bengtsson C, Lissner L, Bjorkelund C. Pre-existing risk factor profiles in users and non-users of hormone replacement therapy: prospective cohort study in Gothenburg, Sweden.[erratum appears in BMJ 2003;327:1381].
39. BMJ 1999; 319: 890–893.
40. Schofield I, Malik R, Izzard A, Austin C, Heagerty A. Vascular structural and functional changes in type 2 diabetes mellitus: evidence for the roles of abnormal myogenic responsiveness and dyslipidemia. Circulation 2002; 106: 3037–3043.
41. Fegan PG, Tooke JE, Gooding KM, Tullett JM, MacLeod KM, Shore AC. Capillary pressure in subjects with type 2 diabetes and hypertension and the effect of antihypertensive therapy. Hypertens 2003; 41: 1111–1117.
42. McNeish AJ, Wilson WS, Martin W Dominant role of an endothelium-derived hyperpolarizing factor (EDHF)-like vasodilator in the ciliary vascular bed of the bovine isolated perfused eye. Br J Pharmacol 2001; 134: 912–920.
43. Blumel JE, Castelo-Branco C, Leal T et al. Effects of transdermal estrogens on endothelial function in postmenopausal women with coronary disease. Climacteric 2003; 6(1):38–44.
44. Squadrito F, Altavilla D, Crisafulli A et al. Effect of genistein on endothelial function in postmenopausal women: a randomized, double-blind, controlled study. Am J Med 2003; 114: 470–476.
45. Hisamoto K, Ohmichi M, Kanda Y et al. Induction of endothelial nitric-oxide synthase phosphorylation by the raloxifene analog LY117018 is differentially mediated by Akt and extracellular signal-regulated protein kinase in vascular endothelial cells. J Biol Chem 2001; 276: 47642–47649.
46. Sugden PH, Clerk A. Akt like a woman: gender differences in susceptibility to cardiovascular disease. Circ Res 2001; 88: 975–977.
47. Mendelsohn ME, Karas RH. The protective effects of estrogen on the cardiovascular system. N Engl J Med 1999; 340: 1801–1811.
48. Haynes MP, Sinha D, Russell KS et al. Membrane estrogen receptor engagement activates endothelial nitric oxide synthase via the PI3-kinase-Akt pathway in human endothelial cells. Circ Res 2000; 87: 677–682.
49. Saltiel AR. Putting the brakes on insulin signaling. N Engl J Med 2003; 349: 2560–2562.
50. Du K, Herzig S, Kulkarni RN, Montminy M. TRB3: a tribbles homolog that inhibits Akt/PKB activation by insulin in liver. Science 2003; 300: 1574–1577.
51. Cushman M, Legault C, Barrett-Connor E et al. Effect of postmenopausal hormones on inflammation-sensitive proteins: the Postmenopausal Estrogen/Progestin Interventions (PEPI) Study. Circulation 1999; 100: 717–722.
52. Berliner JA, Navab M, Fogelman AM et al. Atherosclerosis: basic mechanisms. Oxidation, inflammation, and genetics. Circulation 1995; 91: 2488–2496.
53. Cybulsky MI, Iiyama K, Li H et al. A major role for VCAM-1, but not ICAM-1, in early atherosclerosis. J Clin Investig 2001; 107: 1255–1262.
54. Manning PJ, Sutherland WH, Allum AR, de Jong SA, Jones SD. Effect of hormone replacement therapy on inflammation-sensitive proteins in post-menopausal women with Type 2 diabetes. Diabetic Med 2002; 19: 847–852.
55. Goudev A, Georgiev DB, Koycheva N, Manasiev N, Kyurkchiev S. Effects of low dose hormone replacement therapy on markers of inflammation in postmenopausal women. Maturitas 2002; 43(1):49–53.
56. Silvestri A, Gebara O, Vitale C et al. Increased levels of C-reactive protein after oral hormone replacement therapy may not be related to an increased inflammatory response. Circulation 2003; 107: 3165–3169.
57. Stork S, von Schacky C, Angerer P. The effect of 17beta-estradiol on endothelial and inflammatory markers in postmenopausal women: a randomized, controlled. trial. Atherosclerosis 2002; 165: 301–307.
58. Wakatsuki A, Okatani Y, Ikenoue N, Fukaya T. Effect of medroxyprogesterone acetate on vascular inflammatory markers in postmenopausal women receiving estrogen. Circulation 2002; 105: 1436–1439.
59. Seljeflot I, Arnesen H, Hofstad AE, Os I. Reduced expression of endothelial cell markers after long-term transdermal hormone replacement therapy in women with coronary artery disease. Thromb Haemostas 2000; 83: 944–948.
60. Scarabin PY, Alhenc-Gelas M, Oger E, Plu-Bureau. Hormone replacement therapy and circulating ICAM-1 in postmenopausal women–a randomised controlled trial. Thromb Haemostas 1999; 81: 673–675.
61. Koh KK, Jin DK, Yang SH et al. Vascular effects of synthetic or natural progestagen combined with conjugated equine estrogen in healthy postmenopausal women. Circulation 2001; 103: 1961–1966.
62. Zimmerman GA, McIntyre TM, Prescott SM. Adhesion and signaling in vascular cell-cell interactions. J Clin Invest 1997; 100(11: Suppl): Suppl-5.
63. Kubes P, Kanwar S, Niu XF, Gaboury JP. Nitric oxide synthesis inhibition induces leukocyte adhesion via superoxide and mast cells. FASEB J 1993; 7: 1293–1299.
64. Niu XF, Smith CW, Kubes P. Intracellular oxidative stress induced by nitric oxide synthesis inhibition increases endothelial cell adhesion to neutrophils. Circ Res 1994; 74: 1133–1140.